IONIS PHARMACEUTICALS INC 4

Director-level insider Spencer R. Berthelsen acquired 5,220 shares of Ionis Pharmaceuticals, Inc. common stock via vesting and conversion of Restricted Stock Units.

On July 15, 2026, Spencer R. Berthelsen reported the vesting and settlement of 5,220 Restricted Stock Units (RSUs) into 5,220 shares of Ionis Pharmaceuticals, Inc. common stock, reflecting an exempt Rule 16b-3 transaction coded as an "M" (derivative security conversion). No sale of shares is indicated, and the RSUs converted at a stated price of $0.00 per share, consistent with routine equity compensation vesting. Following the transaction, Berthelsen held 161,233 shares of Ionis common stock directly, plus an additional 70 shares reported as indirectly owned by his daughter, for which he disclaims beneficial ownership. The RSUs represent standard director/insider compensation that vests 100% on the earlier of the first anniversary of the grant date or the next annual shareholder meeting, and is then delivered in whole shares or cash on the following July 15.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

fda

Accession

0000874015-26-000244

Alert Tier

5